Thoratec's HeartMate II Implant Boosts Stroke-Free Survival Four-Fold - Study

Thoratec's next-generation HeartMate II continuous-flow left ventricular assist device enables a more than four-fold increase in two-year survival rate free from stroke and reoperation compared with the firm's HeartMate XVE pulsatile-flow LVAD, according to study data unveiled Nov. 17

More from Archive

More from Medtech Insight